Journal
ARCHIV DER PHARMAZIE
Volume 354, Issue 1, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/ardp.202000163
Keywords
1; 2; 3-triazole hybrids; AIDS; HIV; structure-activity relationship
Ask authors/readers for more resources
This review focuses on the recent advances in 1,2,3-triazole hybrids with potential anti-HIV-1 activity, covering chemical structures, mechanisms of action, and structure-activity relationships from articles published between 2010 and 2020.
The human immunodeficiency virus type 1 (HIV-1) is the major etiological agent responsible for the acquired immunodeficiency syndrome (AIDS), which is a serious infectious disease and remains one of the most prevalent problems at present. Currently, combined antiretroviral therapy is the primary modality for the treatment and management of HIV/AIDS, but the long-term use can result in major drawbacks such as the development of multidrug-resistant viruses and multiple side effects. 1,2,3-Triazole is the common framework in the development of new drugs, and its derivatives have the potential to inhibit various HIV-1 enzymes such as reverse transcriptase, integrase, and protease, consequently possessing a potential anti-HIV-1 activity. This review covers the recent advances regarding the 1,2,3-triazole hybrids with potential anti-HIV-1 activity; it focuses on the chemical structures, structure-activity relationship, and mechanisms of action, covering articles published from 2010 to 2020.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available